CA-FOCAL-SYSTEMS
24.3.2022 13:54:08 CET | Business Wire | Press release
In order to better serve the retail industry with state of the art AI and to couple that with optimal operations and processes, Focal Systems is proud to announce the hiring of Suzy Monford, former Kroger executive, as Chief Strategy and Marketplace Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005148/en/
With more than 30 years’ experience in the grocery and restaurant industries, Monford brings a passion for innovating go-to-market strategies and employing cutting edge technologies that can transform the global food and retail sectors. She will be based in Austin, TX, heading the company’s office there.
“Since 2015 our team has worked with Suzy as a customer, advisor and friend to guide our product roadmap and strategy. Her advice has gotten us to where we are today. She is the smartest person in retail we have had the pleasure of working with. We are thrilled she has elected to join us at this pivotal moment in our company’s growth,” said Francois Chaubard, Focal Systems Founder and CEO. “Her leadership experience as a retailer who’s led e-commerce and technology innovations in the U.S., U. K., and Australia are hugely valuable to us and our customers as we grow around the world.”
“Throughout my career as an operator, marketer and customer experience innovator, I’ve been fortunate to work with best-in-class leaders, so I’m thrilled to join Francois and the Focal team at this moment in our industry’s evolution,” said Monford. “The need to reimagine and rebuild the world’s food economy has never been more vital—to the stores and communities we serve, and more broadly, to the environment.”
After a brief stint with PCC, Monford joins Focal following three years with Kroger. As Group Vice President of eCommerce, she helped create and lead go-to-market strategies for Kroger’s e-commerce partnership with Ocado into new markets across the U.S. During her tenure with Kroger, Monford also served as Group Vice President of Fresh, and President of QFC.
Monford began her supermarket career working for a decade in leadership roles for H-E-B. After H-E-B, she gained international experience with senior executive roles with both Woolworths and Coles, and returned to the U.S. to become CEO of Andronico’s in San Francisco, a company she is credited for turning around as she led its successful acquisition by Albertson’s Safeway.
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state-of-the-art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”- OS that revolutionizes how stores are run. Focal has raised more than $40m to date and scaled solutions on three continents in hundreds of stores, with thousands of cameras deployed. Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
